Form 8-K
8-K — RETRACTABLE TECHNOLOGIES INC
Accession: 0001104659-26-097353
Filed: 2026-08-14
Period: 2026-08-14
CIK: 0000946563
SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)
Item: Other Events
Item: Financial Statements and Exhibits
Documents
8-K — tm2623222d1_8k.htm (Primary)
EX-99 — EXHIBIT 99 (tm2623222d1_ex99.htm)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K — FORM 8-K
8-K (Primary)
Filename: tm2623222d1_8k.htm · Sequence: 1
false
0000946563
0000946563
2026-08-14
2026-08-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported)
August 14, 2026
Retractable Technologies, Inc.
(Exact name of registrant
as specified in its charter)
Texas
001-16465
75-2599762
(State or other jurisdiction
(Commission
(IRS Employer
of incorporation)
File Number)
Identification No.)
511
Lobo Lane, Little
Elm, Texas
75068-5295
(Address of principal executive
offices)
(Zip Code)
Registrant's
telephone number, including area code
(972)
294-1010
None
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b)
of the Act:
Title
of each class
Trading
Symbol(s)
Name
of each exchange on which registered
Common
Stock
RVP
NYSE
American
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01 Other Events.
On August 14, 2026, the Company issued a press
release, a copy of which is attached to this Form 8-K as Exhibit 99, announcing results for the periods ended June 30, 2026.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
99 Press release announcing results for the periods ended June 30, 2026.
104 Cover Page Interactive Date File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
DATE: August 14, 2026
RETRACTABLE TECHNOLOGIES, INC.
(Registrant)
BY:
/s/ John W. Fort III
JOHN W. FORT III
VICE PRESIDENT, CHIEF FINANCIAL OFFICER, AND CHIEF ACCOUNTING OFFICER
EX-99 — EXHIBIT 99
EX-99
Filename: tm2623222d1_ex99.htm · Sequence: 2
Exhibit 99
RETRACTABLE TECHNOLOGIES, INC. RESULTS
FOR THE PERIODS ENDED JUNE 30, 2026
LITTLE ELM, TEXAS, August 14, 2026 —
Retractable Technologies, Inc. (NYSE American: RVP) reports total net sales of $7.2 million for the second quarter of 2026 and an
operating loss of $5.1 million for the period, as compared to total net sales for the same period last year of $10.4 million and an operating
loss of $5.1 million. For the first half of the year, net sales were $14.4 million and operating losses were $11.3 million as compared
to 2025 net revenues of $18.7 million and operating losses of $9.8 million.
While the majority of flu season sales typically
occur in the third quarter, in 2025, purchasing patterns differed with unusually high unit sales related to flu season products in the
second quarter of 2025, impacting comparability to second quarter 2026 unit sales related to flu season products, which follows a more
traditional purchasing pattern.
Domestic production increased to 42.4% of the
units manufactured during the first six months of 2026 compared to 38% of units produced domestically for the first six months of 2025.
Additionally, as previously reported, a reduction in force in April 2026 is expected to result in cost savings in future periods.
Our net income (loss) for the three and six months
ended June 30, 2026 was $2.8 million and $(1.4) million, respectively, including a $6.4 million gain on the sale of equity securities
in the second quarter of 2026.
Comparison of Three Months Ended June 30,
2026 and June 30, 2025
Domestic sales accounted for 81.6% and 81.3% of
total revenues for the three months ended June 30, 2026 and 2025, respectively. Domestic revenues decreased 30.8%, while domestic
unit sales decreased 35.1%. Domestic unit sales represented 70.3% of total unit sales for the three months ended June 30, 2026 compared
to 68.9% for the same period last year. The decrease in sales and units was primarily due to the timing of EasyPoint® product
orders from certain customers, which can fluctuate between periods based on customer purchasing patterns.
International revenues for the three months ended
June 30, 2026 decreased 32.2% compared to the same period in 2025. The decrease in international sales was primarily driven by a
decrease in EasyPoint® needle sales. Traditionally, international sales carry lower average selling prices compared to
our domestic sales. There remains uncertainty regarding the timing of future international orders.
Overall, units sales decreased 36.4% due to a
decrease in EasyPoint® needle sales.
Cost of manufactured product decreased 34.7% compared
to the same period last year primarily due to a decrease in sales. Royalty expense decreased 20.8% due to the decrease in gross sales.
Tariffs may continue to materially impact our
costs in future periods. Approximately $46 thousand was spent on tariff expenses in the second quarter of 2026. The reduction in tariff
costs compared to prior periods is attributable to ongoing mitigation efforts, including strategic sourcing decisions and increased domestic
production. These costs are included in Cost of manufactured product.
Operating expenses remained consistent in the
three months ended June 30, 2026 and 2025.
The loss from operations was $5.1 million for
the three months ended June 30, 2026 and 2025.
The unrealized loss on debt securities was $179
thousand for the second quarter of 2026 due to the decreased market values of those securities. The realized gain from the sale of equity
was $6.4 million in the second quarter of 2026.
The provision for income taxes was $1.8 thousand
for the three months ended June 30, 2026 and 2025.
Comparison of Six Months Ended June 30,
2026 and June 30, 2025
Domestic sales accounted for 82.2% and 85.0% of
total revenues for the six months ended June 30, 2026 and 2025, respectively. Domestic revenues decreased 25.8%, while domestic unit
sales decreased 25.0%. Domestic unit sales represented 71.2% of total unit sales for the six months ended June 30, 2026 compared
to 74.9% for the same period last year. The decrease in sales was primarily due to a decrease in EasyPoint® needle unit
sales.
International revenues for the six months ended
June 30, 2026 decreased 9.3% compared to the same period in 2025. Traditionally, international sales carry lower average selling
prices compared to our domestic sales. There remains uncertainty regarding the timing of future international orders.
Overall, units sales decreased 21%.
Cost of manufactured product decreased 20.8% compared
to the same period last year primarily due to a decrease in units sold. Royalty expense decreased 14.4% due to the decrease in gross sales.
Tariffs may continue to materially impact our
costs in future periods. Approximately $58 thousand was spent on tariff expenses in the first six months of 2026. The reduction in tariff
costs compared to prior periods is attributable to ongoing mitigation efforts, including strategic sourcing decisions and increased domestic
production. These costs are included in Cost of manufactured product.
Operating expenses increased 10.0% primarily due
to donation expense.
The loss from operations was $11.3 million compared
to a loss of approximately $9.8 million for the same period last year. The increase in loss from operations was primarily driven by a
decrease in revenue and increase in operating expenses due to donation expense.
The unrealized gain on debt securities was $13
thousand for the six months ended June 30, 2026 due to the increased market values of those securities. The realized gain from the
sale of equity was $6.4 million in the first six months of 2026.
The provision for income taxes was $3.7 thousand
as compared to a benefit for income taxes of $288 thousand for the same period in 2025. The change is primarily due to a decrease in the
net loss in the current period.
ABOUT RETRACTABLE
Retractable manufactures and markets VanishPoint®
and Patient Safe® safety medical products and the EasyPoint® needle. The VanishPoint® syringe,
blood collection, and IV catheter products are designed to prevent needlestick injuries and product reuse by retracting the needle directly
from the patient, effectively reducing exposure to the contaminated needle. Patient Safe® syringes are uniquely designed
to reduce the risk of bloodstream infections resulting from catheter hub contamination. The EasyPoint® is a retractable
needle that can be used with luer lock syringes, luer slip syringes, and prefilled syringes to give injections. The EasyPoint®
needle also can be used to aspirate fluids and for blood collection. Retractable's products are distributed by various specialty and general
line distributors.
For more information on Retractable, visit its
website at www.retractable.com.
Forward-looking statements in this press release
are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995 and reflect Retractable's current
views with respect to future events. Retractable believes that the expectations reflected in such forward-looking statements are accurate.
However, Retractable cannot assure you that such expectations will materialize. Actual future performance could differ materially from
such statements.
Factors that could cause or contribute to such
differences include, but are not limited to: tariffs; material changes in demand; Retractable's ability to maintain liquidity; Retractable's
maintenance of patent protection; Retractable's ability to maintain favorable third party manufacturing and supplier arrangements and
relationships; foreign trade risk; Retractable's ability to access the market; production costs; the impact of larger market players in
providing devices to the safety market; and other risks and uncertainties that are detailed from time to time in Retractable's periodic
reports filed with the U.S. Securities and Exchange Commission.
Retractable Technologies, Inc.
John W. Fort III, 888-806-2626 or 972-294-1010
Vice President, Chief Financial Officer, and Chief
Accounting Officer
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 7
v3.26.1
Cover
Aug. 14, 2026
Cover [Abstract]
Document Type
8-K
Amendment Flag
false
Document Period End Date
Aug. 14, 2026
Entity File Number
001-16465
Entity Registrant Name
Retractable Technologies, Inc.
Entity Central Index Key
0000946563
Entity Tax Identification Number
75-2599762
Entity Incorporation, State or Country Code
TX
Entity Address, Address Line One
511
Lobo Lane
Entity Address, City or Town
Little
Elm
Entity Address, State or Province
TX
Entity Address, Postal Zip Code
75068-5295
City Area Code
972
Local Phone Number
294-1010
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Title of 12(b) Security
Common
Stock
Trading Symbol
RVP
Security Exchange Name
NYSEAMER
Entity Emerging Growth Company
false
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration